Therapeutic Asset Ratings

130 results matching 1 filter

133,990 assets · 8,802 sponsors · 3,128 indications

Methodology v0.2

Asset	Sponsor	Phase	Rating
Oxygen Major Depressive Disorder	Unity Health Toronto	P4	B (59)
Lsd Major Depressive Disorder	Johns Hopkins University	P2	B (59)
Pdc-1421 Major Depressive Disorder	BioLite, Inc.	P2	B (59)
Pentoxifylline Major Depressive Disorder	Hawler Medical University	P2	B (59)
Namenda Major Depressive Disorder	Jeffrey Miller	P2/3	B (59)
Guanfacine Major Depressive Disorder	Stanford University	P4	B (58)
LEVODOPA Major Depressive Disorder	Charite University, Berlin, Germany	P4	B (58)
MT-5199 Major Depressive Disorder	Neurocrine Biosciences	P4	B (58)
Vts-K Major Depressive Disorder	Theresa Jacob, PhD, MPH	P4	B (58)
Humulin R Major Depressive Disorder	University Health Network, Toronto	P3	B (58)
LY-2940094 Major Depressive Disorder	Mclean Hospital	P2	B (58)
Ropanicant Major Depressive Disorder	Suven Life Sciences Limited	P2	B (58)
Alto-100 Major Depressive Disorder	Alto Neuroscience	P2	B (57)
SPL026 Major Depressive Disorder	Small Pharma Ltd	P1/2	B (57)
Daridorexant Major Depressive Disorder	Institut d'Investigació Biomèdica de Bellvitge	P4	B (56)
Azetukalner Major Depressive Disorder	Xenon Pharmaceuticals Inc.	P3	B (56)
Osavampator Major Depressive Disorder	Neurocrine Biosciences	P3	B (56)
Prometrium Major Depressive Disorder	University of North Carolina, Chapel Hill	P4	CCC (55)
Apimostinel Major Depressive Disorder	Syndeio Biosciences, Inc	P2	CCC (55)
Onfasprodil Major Depressive Disorder	Novartis Pharmaceuticals	P2	CCC (55)
sp-624 Major Depressive Disorder	Sirtsei Pharmaceuticals, Inc.	P2	CCC (55)
Phenelzine Major Depressive Disorder	University of California, San Francisco	P4	CCC (54)
Modafinil Major Depressive Disorder	University of Minnesota	P3	CCC (54)
Solriamfetol Major Depressive Disorder	Axsome Therapeutics, Inc.	P3	CCC (54)
Alto-100 Po Major Depressive Disorder	Alto Neuroscience	P2	CCC (54)

Showing 51 to 75 of 130 assets

PreviousPage 3 of 6Next